Progress and challenges in anti-obesity pharmacotherapy

Area of Science:

• Metabolic disease research
• Pharmacology
• Obesity medicine

Background:

• Obesity presents a significant global health challenge, with lifestyle interventions yielding modest and unsustainable weight loss due to physiological adaptations promoting weight regain.
• Pharmacotherapy is an established adjunct for other metabolic diseases, yet its application in obesity treatment faces challenges.
• Approved anti-obesity drugs, including GLP-1 receptor agonists, offer greater efficacy than lifestyle changes alone but have limited patient utilization.

Purpose of the Study:

• To review the landscape of approved anti-obesity pharmacotherapies.
• To discuss barriers to the adoption of anti-obesity medications.
• To highlight future directions in anti-obesity drug development.

Main Methods:

• Review of currently approved anti-obesity medications in major global markets (USA, EU, Australia, Japan).
• Analysis of drug classes, efficacy, and side-effect profiles.
• Discussion of factors influencing clinical acceptance and insurance coverage.

Main Results:

• Multiple classes of anti-obesity drugs exist, demonstrating superior weight loss compared to lifestyle interventions alone.
• Significant barriers to patient access include safety/efficacy concerns, inadequate insurance coverage, and prevailing clinician/patient beliefs about willpower.
• Novel multi-agonist molecules targeting gut hormones represent a promising area for future drug development.

Conclusions:

• Anti-obesity medications are effective tools that should be considered alongside lifestyle interventions.
• Addressing concerns regarding safety, efficacy, insurance coverage, and societal beliefs is crucial for increasing medication uptake.
• Future research should focus on developing innovative therapies, such as multi-agonist drugs, to improve obesity management.